Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Jul 27, 2024; 16(7): 2270-2280
Published online Jul 27, 2024. doi: 10.4240/wjgs.v16.i7.2270
Published online Jul 27, 2024. doi: 10.4240/wjgs.v16.i7.2270
Effectiveness of colonoscopy, immune fecal occult blood testing, and risk-graded screening strategies in colorectal cancer screening
Ming Xu, Tao Meng, Department of Colorectal Surgery, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Qingdao 266000, Shandong Province, China
Jing-Yi Yang, Department of Gastrointestinal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China
Author contributions: Xu M wrote the manuscript; Yang JY collected the data; Meng T guided the study. All authors reviewed, edited, and approved the final manuscript and revised it critically for important intellectual content, gave final approval of the version to be published, and agreed to be accountable for all aspects of the work.
Institutional review board statement: This study was approved by the Medical Ethics Committee of The First Affiliated Hospital of Zhengzhou University.
Clinical trial registration statement: This study is a national multicenter RCT of colorectal cancer screening in the population [TARGET-C study, Chinese Clinical Trial Platform (http://www.chitr.org.cn)].
Informed consent statement: Informed consent was obtained from all the patients for this study.
Conflict-of-interest statement: The authors declare no conflicts of interest for this article.
Data sharing statement: The data in this study support the principles of transparent science, and the corresponding data sets can be shared with the scientific community upon reasonable request. For detailed data access and usage rules, please contact the person in charge of this study: jingyi_yang1613@163.com.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tao Meng, Doctor, Department of Colorectal Surgery, Qilu Hospital (Qingdao), Cheeloo College of Medicine, No. 758 Hefei Road, Qingdao 266000, Shandong Province, China. 18561810550@163.com
Received: February 14, 2024
Revised: May 15, 2024
Accepted: May 27, 2024
Published online: July 27, 2024
Processing time: 158 Days and 19.1 Hours
Revised: May 15, 2024
Accepted: May 27, 2024
Published online: July 27, 2024
Processing time: 158 Days and 19.1 Hours
Core Tip
Core Tip: A multicenter randomized controlled trial was conducted to investigate the role of colonoscopy combined with immune fecal occult blood test in colorectal cancer screening and establish a risk classification model. The efficacy and safety of the screening methods were evaluated by comparing the colorectal cancer detection rate, early diagnosis rate, and adverse event rate of the screening group and the control group. At the same time, the collected data were used to construct risk classification models for different risk groups, so as to realize individual screening management of subjects.